Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
OB
Orchestra BioMed Holdings, Inc. Ordinary Shares
OBIO
Mkt Cap
$326.1M
Volume
415.93K
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
OB
OBIO
OB
Orchestra BioMed Holdings, Inc. Ordinary Shares
OBIO
News
·
Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes
Mkt Cap
$345.0M
Volume
415.93K
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Insider
Filings
Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced its inclusion in the Russell 3000 Index and Russell 2000 Index following the 2026 Russell indexes reconstitution effective June 26, 2026. The biomedical company develops AVIM Therapy for hypertension in collaboration with Medtronic and Virtue SAB for atherosclerotic artery disease, both undergoing pivotal clinical trials.
GlobeNewswire Inc. · Jun 29, 2026
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
Orchestra BioMed (OBIO) announced its participation in two major institutional investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference (March 3rd) and the Barclays 28th Annual Global Healthcare Conference (March 11th). Management will conduct fireside chats and one-on-one investor meetings at both events.
GlobeNewswire Inc. · Feb 19, 2026
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
Orchestra BioMed initiated a pivotal U.S. clinical trial comparing its Virtue Sirolimus AngioInfusion Balloon to a paclitaxel-coated balloon for treating coronary in-stent restenosis, with 740 patients expected to be enrolled across 75 centers by mid-2027.
GlobeNewswire Inc. · Oct 27, 2025
Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
Orchestra BioMed presented clinical data showing AVIM therapy can sustainably reduce blood pressure in patients, with effects that are reversible and reproducible upon reactivation after a washout period.
GlobeNewswire Inc. · Sep 4, 2025
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
Orchestra BioMed received FDA approval to expand patient eligibility for its BACKBEAT study, potentially increasing the eligible patient pool by over 24-fold and supporting its mid-2026 enrollment target for AVIM therapy in treating uncontrolled hypertension.
GlobeNewswire Inc. · Aug 8, 2025
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
Orchestra BioMed's AVIM therapy has received FDA Breakthrough Device Designation for treating uncontrolled hypertension in patients with increased cardiovascular risk, regardless of pacemaker indication. The company is currently enrolling the BACKBEAT global pivotal study to further evaluate the safety and efficacy of AVIM therapy.
GlobeNewswire Inc. · Apr 23, 2025
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference
Orchestra BioMed presented data at the THT 2025 Conference showing that its AVIM therapy significantly improved echocardiographic markers of diastolic dysfunction, an important component in the development of heart failure, in hypertensive patients.
GlobeNewswire Inc. · Feb 12, 2025
Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors
Orchestra BioMed, a biomedical company, announced the appointment of Christopher Cleary, a former Medtronic executive, to its Board of Directors. Cleary brings over three decades of experience in corporate development, mergers, and strategic collaborations, which aligns with Orchestra BioMed's partnership-enabled business model.
GlobeNewswire Inc. · Feb 5, 2025
Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar?
Orchestra BioMed Holdings, Inc. (OBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks Investment Research · Jun 24, 2024
All You Need to Know About Orchestra BioMed Holdings, Inc. (OBIO) Rating Upgrade to Buy
Orchestra BioMed Holdings, Inc. (OBIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research · Jun 3, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
OB
OBIO
Orchestra BioMed Holdings, Inc. Ordinary Shares
Buy
Sell
Market
Limit
Soon
OBIO
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any OBIO yet.
Related Tickers
Earnings